ZURA

Over the past six months (April to October 2026), Zura Bio Ltd. experienced several stock-impacting events. In February 2026, a public offering raised approximately $144 million. Q1 2026 financial results on May 7, 2026, led to a -7.16% stock change. On May 13, 2026, the appointment of a new Chief Business Officer resulted in a +1.05% stock change. Exceeding enrollment targets in Phase 2 studies for tibulizumab on June 29, 2026, caused a +5.23% stock increase. Q2 2026 financial results on August 11, 2026, reported a net loss of $26.3 million and cash of $205.1 million, leading to a -1.24% change. Analyst price target increases from Wedbush and Guggenheim on August 24, 2026, contributed to a +7.69% stock increase. Participation in the Cantor Global Healthcare Conference on August 31, 2026, resulted in a +1.99% stock increase. On October 7, 2026, Zura Bio's shares rose approximately 9.5% after Merck presented positive Phase 2b data for its HS treatment. Overall, the stock decreased by 35.97% in the past month, 9.56% over the last 12 months, and had a year-to-date return of -25.10%.